SCHEMBL120913

SCHEMBL120913

OCc1cc2ccccc2nc1Cl

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.70
ALDH1A1 P00352 7/20 0.57
KDM4E B2RXH2 5/20 0.57
GLA P06280 2/20 0.46
MAPT P10636 2/20 0.46
HPGD P15428 2/20 0.46
ACHE P22303 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
FAAH O00519 1/20 0.45
PDE10A Q9Y233 1/20 0.45
HTT P42858 1/20 0.44
MEN1 O00255 1/20 0.44
NPSR1 Q6W5P4 1/20 0.42
EGFR P00533 1/20 0.42
TOP2A P11388 1/20 0.42
TOP2B Q02880 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.40
TLR8 Q9NR97 2/20 0.40
GAA P10253 1/20 0.40
STAT3 P40763 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30162631 0.82 KMT2A (1.00) KMT2AALDH1A1KDM4EGLAMAPT
SCHEMBL377259 0.82 KMT2A (1.00) KMT2AALDH1A1KDM4EGLAMAPT
SCHEMBL29518150 0.81 KMT2A (0.70) KMT2AALDH1A1KDM4EGLAMAPT
SCHEMBL681071 0.81 KMT2A (0.70) KMT2AALDH1A1KDM4EGLAMAPT
SCHEMBL8735682 0.81 KMT2A (0.70) KMT2AALDH1A1KDM4EGLAMAPT
SCHEMBL4358158 0.81 KMT2A (0.70) KMT2AALDH1A1KDM4EGLAMAPT
SCHEMBL13067261 0.81 KMT2A (0.70) KMT2AALDH1A1KDM4EGLAMAPT
SCHEMBL2908933 0.79 KMT2A (0.62) KMT2AALDH1A1KDM4EGLAMAPT
SCHEMBL22744558 0.79 KMT2A (0.57) KMT2AALDH1A1KDM4EMAPTFAAH
SCHEMBL29370497 0.78 ALDH1A1 (0.48) KMT2AALDH1A1KDM4EGLAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114957112-B (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof 渤海大学 2023-01-17 CN claimed
CN-114957112-A (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof 渤海大学 2022-08-30 CN claimed
EP-4691558-A2 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS University Court of The University of Dundee (GB) 2026-02-11 EP disclosed
US-20250295789-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2025-09-25 US disclosed
EP-2857018-B1 Treatment or prophylaxis of proliferative conditions UNIV COURT OF THE UNIV OF DUNDEE (GB) 2025-09-03 EP disclosed
CN-117736205-A Fused ring compounds as MC4R antagonists, pharmaceutical compositions and their use in medicine 长春金赛药业有限责任公司 2024-03-22 CN disclosed
CN-114957112-B (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof 渤海大学 2023-01-17 CN disclosed
CN-114957112-B (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof 渤海大学 2023-01-17 CN disclosed
CN-114957112-A (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof 渤海大学 2022-08-30 CN disclosed
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2022-02-03 US disclosed
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2022-02-03 US disclosed
US-5981542-A TOPOISOMERASE INHIBITORS; ANTITUMORAL DRUGS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-11-09 US disclosed
EP-0946567-A1 NOVEL COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-10-06 EP disclosed
EP-0946566-A1 PRO-DRUGS AND COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-10-06 EP disclosed
WO-1999033829-A1 NOVEL CAMPTOTHECIN TETRACYCLIC ANALOGUES, PREPARATION, METHODS, APPLICATIONS AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-07-08 WO disclosed
CN-1192740-A Novel camptothecin analogues, their preparation method, their pharmaceutical use and their pharmaceutical compositions SOD CONSEILS RECH APPLIC (FR) 1998-09-09 CN disclosed
WO-1998028304-A1 PRO-DRUGS AND COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1998-07-02 WO disclosed
WO-1998028305-A1 NOVEL COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1998-07-02 WO disclosed
EP-0835258-A1 NOVEL CAMPTOTHECIN ANALOGUES, PREPARATION METHODS THEREFOR, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID ANALOGUES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1998-04-15 EP disclosed
WO-1997000876-A1 NOVEL CAMPTOTHECIN ANALOGUES, PREPARATION METHODS THEREFOR, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID ANALOGUES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) 1997-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 KMT2A 2458/4885ALDH1A1 55/4885KDM4E 3646/4885
US-20250295789-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, BRCA1, UGT1A1 KMT2A 2169/4885ALDH1A1 32/4885KDM4E 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.